Literature DB >> 29270757

Three dimensional orbital magnetic resonance T2-mapping in the evaluation of patients with Graves' ophthalmopathy.

Kai Hou1, Tao Ai2, Wei-Kun Hu3, Ban Luo3, Yi-Ping Wu4, Rong Liu5.   

Abstract

The clinical application of orbital magnetic resonance (MR) T2-mapping imaging in detecting the disease activity of Graves' ophthalmopathy (GO), and the predictive values of therapy response to intravenous glucocorticoid (ivGC) were investigated. Approved by the local institutional review board (IRB), 106 consecutive patients with GO were included in this prospective study. All subjects were divided into two groups according to the patients' clinical activity score (CAS): the CAS positive group (CAS ≥3) or the CAS negative group (CAS <3). T2 relaxation time of extraocular muscles (T2RT; ms) and the areas of four extra-ocular muscles (AEOMs; mm2) were measured by 3D T2-mapping MR sequence before and after methylprednisolone treatment, so as the CAS and some ophthalmic examinations including visual acuity, intra-ocular pressure, eyeball movement, diplopia and proptosis. In addition, 24 healthy volunteers were recruited as the control group. The mean T2RT and AEOMs in CAS positive group were higher than those in CAS negative group. Both CAS positive and negative groups had significantly higher mean T2RT and AEOMs than the control group (P<0.01). There was a positive correlation between T2RT and AEOMs values in GO patients, both of them had a positive correlation with CAS and the ophthalmic examinations. It was concluded that to evaluate the activity of GO, CAS was mostly related to inflammation symptoms of ocular surface, more than that, T2RT and AEOMs were also related to abnormal findings of the ophthalmic examinations including high ocular pressure, impaired eyeball movement, diplopia and proptosis. T2RT and AEOMs can reflex the inflammation state of ocular muscles better. CAS combined with 3D T2-mapping MR imaging could improve the sensitivity of detection of active GO so as the prediction and evaluation of the response to methylprednisolone treatment.

Entities:  

Keywords:  Graves’ ophthalmopathy; magnetic resonance; methylprednisolone

Mesh:

Substances:

Year:  2017        PMID: 29270757     DOI: 10.1007/s11596-017-1831-8

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  12 in total

1.  Evaluation of rectus extraocular muscles using dynamic contrast-enhanced MR imaging in patients with Graves' ophthalmopathy for assessment of disease activity.

Authors:  Hong Jiang; Zhenchang Wang; Junfang Xian; Jing Li; Qinghua Chen; Likun Ai
Journal:  Acta Radiol       Date:  2011-12-07       Impact factor: 1.990

2.  Evaluation of the patients with Grave's ophthalmopathy after the corticosteroids treatment.

Authors:  Mirjana Janićijević Petrović; Tatjana Sarenac; Suncica Srećković; Marko Petrović; Dejan Vulović; Katarina Janićijević
Journal:  Vojnosanit Pregl       Date:  2012-03       Impact factor: 0.168

3.  Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immunosuppressive therapy for Graves' ophthalmopathy.

Authors:  Seigo Tachibana; Tsukasa Murakami; Hitoshi Noguchi; Yasushi Noguchi; Akiko Nakashima; Yufuko Ohyabu; Shiro Noguchi
Journal:  Endocr J       Date:  2010-08-19       Impact factor: 2.349

4.  Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.

Authors:  Luigi Bartalena; Lelio Baldeschi; Alison Dickinson; Anja Eckstein; Pat Kendall-Taylor; Claudio Marcocci; Maarten Mourits; Petros Perros; Kostas Boboridis; Antonella Boschi; Nicola Currò; Chantal Daumerie; George J Kahaly; Gerasimos E Krassas; Carol M Lane; John H Lazarus; Michele Marinò; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Simon Pearce; Aldo Pinchera; Susanne Pitz; Mario Salvi; Paolo Sivelli; Matthias Stahl; Georg von Arx; Wilmar M Wiersinga
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

5.  Association of polymorphisms of rs179247 and rs12101255 in thyroid stimulating hormone receptor intron 1 with an increased risk of Graves' disease: A meta-analysis.

Authors:  Jing Gong; Shu-Jun Jiang; Ding-Kun Wang; Hui Dong; Guang Chen; Ke Fang; Jin-Rui Cui; Fu-Er Lu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28

Review 6.  Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity.

Authors:  S Zang; K A Ponto; G J Kahaly
Journal:  J Clin Endocrinol Metab       Date:  2011-01-14       Impact factor: 5.958

7.  MR T2 relaxation time for the assessment of retrobulbar inflammation in Graves' ophthalmopathy.

Authors:  C I Utech; U Khatibnia; P F Winter; K G Wulle
Journal:  Thyroid       Date:  1995-06       Impact factor: 6.568

8.  Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study.

Authors:  Rob J van Geest; Inna V Sasim; Hans P F Koppeschaar; Rachel Kalmann; Simone N Stravers; Ward R Bijlsma; Maarten P Mourits
Journal:  Eur J Endocrinol       Date:  2008-02       Impact factor: 6.664

9.  Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.

Authors:  M L Tanda; E Piantanida; L Liparulo; G Veronesi; A Lai; L Sassi; N Pariani; D Gallo; C Azzolini; M Ferrario; L Bartalena
Journal:  J Clin Endocrinol Metab       Date:  2013-02-13       Impact factor: 5.958

10.  Long-term multidisciplinary follow-up of unilateral thyroid-associated orbitopathy.

Authors:  Ch Daumerie; Th Duprez; A Boschi
Journal:  Eur J Intern Med       Date:  2008-03-18       Impact factor: 4.487

View more
  3 in total

Review 1.  Extraocular muscle enlargement.

Authors:  Khizar Rana; Valerie Juniat; Sandy Patel; Dinesh Selva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-17       Impact factor: 3.535

2.  T2 Mapping with and without Fat-Suppression to Predict Treatment Response to Intravenous Glucocorticoid Therapy for Thyroid-Associated Ophthalmopathy.

Authors:  Linhan Zhai; Qiuxia Wang; Ping Liu; Ban Luo; Gang Yuan; Jing Zhang
Journal:  Korean J Radiol       Date:  2022-04-26       Impact factor: 7.109

3.  Baseline Volumetric T2 Relaxation Time Histogram Analysis: Can It Be Used to Predict the Response to Intravenous Methylprednisolone Therapy in Patients With Thyroid-Associated Ophthalmopathy?

Authors:  Ping Liu; Ban Luo; Lang Chen; Qiu-Xia Wang; Gang Yuan; Gui-Hua Jiang; Jing Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-25       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.